epiMOGRIFY PLATFORM

Systematically identify the epigenetically-predicted factors required
to drive and maintain cell identity.

epiMOGRIFY is an extension of the Company’s proprietary direct cellular reprogramming technology, MOGRIFY®, that enables the identification of the optimal culture conditions required to maintain cells and support reprogramming in chemically defined media. This can be applied in cGMP manufacture and enhances directed differentiation or transdifferentiation to support the development of scalable off-the-shelf therapies for diseases with a high unmet clinical need.

epiMOGRIFY combines gene-regulatory information with a model of a cell’s epigenetic landscape and leverages changes in the level of DNA-histone methylation (H3K4me3 modifications). The platform utilizes data from more than 100 human cell/tissue types (available via the ENCODE and Epigenome Roadmap consortia) to accurately define culture conditions that can maintain the cell identity or induce cell conversion.

The predictive power of epiMOGRIFY has been validated in two ways: cell maintenance and differentiation. epiMOGRIFY-predicted factors are able to maintain astrocytes and cardiomyocytes in vitro in chemically defined media, and promote the generation of astrocytes and cardiomyocytes from neural progenitors and embryonic stem cells, respectively. In both cell maintenance and differentiation, epiMOGRIFY defined conditions performed as well or better in all cases when compared to existing undefined conditions, significantly increasing cell growth and survival, as well as resulting in a higher differentiation efficiency.

EpiMogrify - Identify Optimal Culture Conditions

Step 1 H3K4me3 histone modification sequencing using ChIP-seq (chromatin-immunoprecipitation)

EPIMOGRIFY 02

Step 2 Cell identity gene identification using ChIP-seq data (ENCODE)

EPIMOGRIFY 03

Step 3 Key receptor identification, using the same “engine” as MOGRIFY® (considers both direct and indirect effects)

EPIMOGRIFY 04

Step 4 Ligand identification for both paracrine & autocrine ligands

Patent pending on the epiMOGRIFY platform, validated conversion and maintenance of specific cell types. Images adapted from Kamaraj et al., EpiMogrify Models H3K4me3 Data to Identify Signaling Molecules that Improve Cell Fate Control and Maintenance. Cell Systems (2020).

webinar-the-epigenetics-approach-to-driving-cell-identity-and-scalability-in-cell-therapy

Applying Mogrify and epiMOGRIFY

IN THE DEVELOPMENT OF CELL & GENE THERAPIES

Efficacy

  • Enhances existing stem-cell forward reprogramming methods.
  • Bypasses development pathways altogether, affecting direct transdifferentiation between a mature cell type to another.

Safety

  • Produces mature cells to avoid the tumorigenicity- and immunogenicity-associated characteristics of pluripotent stem cells.
  • Queries FANTOM5 and other proprietary data sources to improve prediction quality, prediction accuracy and cell reprogramming efficacy.

Scalability

  • Produces any target cell type from any source cell type.
  • Identifies the optimal culture conditions required to maintain and support the reprogramming of cells in chemically defined media.
  • Capacity to identify small molecules known to affect the expression of the key MOGRIFY® predicted transcription factors, avoiding the need for their transduction, and offering greater potential as an in vivo reprogramming therapy.

Our

PIPELINE

AREA Sample Acquisition Bioinformatics In vitro PoC In vivo PoC IND Clinical Marketing
Immunotherapy (Oncology) mogrify mogrify mogrify mogrify partner partner
Ophthalmology (Retinal) mogrify mogrify mogrify partner partner
Collaborations (Pulmonary, Metabolic & Others) mogrify mogrify mogrify partner partner partner partner
mogrify Mogrify Progress partner Expect to Partner